BASKING RIDGE, N.J.--(BUSINESS WIRE)--VioQuest Pharmaceuticals (OTCBB: VOQP) announced today that data from a phase 1 clinical trial for Lenocta™ (sodium stibogluconate) will be presented during an oral session titled “Developmental Therapeutics: Immunotherapy” at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting being held May 30 to June 3, 2008 at the McCormick Place Convention Center in Chicago, Illinois.
